What VCs Really Want (and How Biotech Startups Can Deliver)

By Jenna Levenson, PhD, RN, MS

BioTech innovation is booming—but funding is not automatic. While scientific breakthroughs attract attention, securing venture capital requires more than compelling data. Investors are scrutinizing pipelines, leadership, and execution potential with more rigor than ever.

What do venture capitalists want and how can startups position themselves to get a “yes”?

Let’s break it down.

What VCs Are Looking For

1. Clear Problem, Clear Solution

VCs fund transformation—not just science. Your platform must solve a significant, well-defined problem. “Me-too” products or fuzzy pipelines won’t get far.

Pro Tip: Distill your science into real-world impact. Can you explain your value proposition to a non-scientist in under 60 seconds?

2. Strong, Coachable Leadership

Founders do not need all the answers—but they do need vision, adaptability, and grit. VCs are investing in the team just as much as the molecule.

Pro Tip: Highlight your team’s scientific credibility and your willingness to learn, collaborate, and pivot when needed.

3. De-Risked Development Path

Risk is part of the game—but strategic planning reduces avoidable pitfalls. VCs look for thoughtful regulatory strategy, credible preclinical or early clinical data, and go/no-go decision points.

Pro Tip: Demonstrate your understanding of regulatory requirements (IND-enabling, FDA interactions, trial feasibility, etc.) and how you’ll use funding wisely.

4. IP and Competitive Moat

If you cannot protect it, you cannot scale it. Patents, exclusivity periods, and trade secrets matter deeply to investors.

Pro Tip: Include an IP summary and competitive landscape analysis in your deck—be honest, not overly optimistic.

5. Defined Milestones and Use of Funds

VCs want to see that every dollar has a mission. Clear, achievable development milestones (especially ones that increase valuation) are key.

Pro Tip: Break down your next 12–24 months into tangible progress indicators: IND filing, lead candidate selection, partnership discussions, etc.

How BioTechs Can Build Better VC Relationships

Engage Early—Even Before You Are Ready

Ask for advice, not money. Relationship-building goes further than a cold pitch ever will.

Be Transparent

Missed a milestone? Share what happened and what is next. VCs appreciate honesty and accountability.

Invest in Communication

Scientific complexity is no excuse for poor storytelling. Your data won’t speak for itself if no one understands it.

VCs do not just want a home run—they want a well-run base hit that can scale.

BioTech founders who combine strong science with smart business strategy are better positioned to secure funding, build trust, and get therapies to patients faster.

Key Takeaways

• VCs fund clarity, not confusion—make your science simple and your path clear.

• Show that you have thought about IP, regulatory timelines, and valuation inflection points.

• Relationships matter—start early and engage authentically.

Let's Keep the Conversation Going

Download my free biotech workbooks here, or connect with me on LinkedIn to talk strategy, funding, or AI in clinical development.